NASDAQ:TERN News 16 December 2025 - 14 January 2026

NEW YORK, December 30, 2025, 15:30 ET — Regular session. Shares of Terns Pharmaceuticals, Inc. fell 2.8% to $40.34 in afternoon trading on Tuesday, after swinging between $39.99 and $41.98. The pullback puts the stock back around $40, the price used in the company’s recent upsized equity offering — a level traders often watch after a big deal resets supply and demand. That matters now because Terns’ December financing and trial update put new attention on how quickly the biotech can turn early leukemia data into larger studies, while also giving it a much longer cash runway. Biotech shares were

December 18, 2025 — Terns Pharmaceuticals, Inc. (NASDAQ: TERN) is pulling back in Thursday trading after one of the most explosive biotech runs of the year, with investors digesting a fresh wave of clinical-trial enthusiasm, a major equity raise, and a fast-updating stack of Wall Street price targets. As of the latest available trading update on Dec. 18, 2025, TERN stock was around $39.62, after opening near $42.55 and trading in a $39.62–$42.59 intraday range, with volume above 2.0 million shares. That dip doesn’t erase the bigger story: Terns has already repriced dramatically higher in recent weeks—driven by attention around

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) is still living inside one of the more dramatic biotech story arcs of 2025: eye-popping clinical data, followed immediately by a massive equity raise, followed by a flurry of analyst price-target resets. As of Tuesday, December 16, 2025, TERN shares were trading around $44. That price level matters because it sits right on top of the two big forces investors have been digesting all month: Below is a complete, publication-ready roundup of the current news, forecasts, and market analysis shaping Terns Pharmaceuticals stock as of 16.12.2025, plus the catalysts that could drive the next move.